![](https://investorshub.advfn.com/uicon/822788.png?cb=1664635735)
Saturday, August 26, 2023 3:13:15 PM
Your posts represent misinformation in my view.
Thanks for posting an article from 2018, but there have been significant developments since 2018.
Rather than entertaining the noise of baseless distractions, I would suggest researching the evidence supporting the vast significance of Liau’s work and the further development of this technology in combination with other technologies. DCVax-L is already supported by peer-reviewed clinical evidence, but there is much more to the story that is yet to unfold, and the SP will follow the regulatory developments worldwide.
Targeted individualized combo therapies are emerging as the defining feature of a new era of oncology. Just look at the impact that PD1 blockade technology has had on the field of oncology in recent years!
![](http://investorshub.advfn.com/uimage/uploads/2022/11/7/zlawr4CEFDFB7-1186-4B78-BD25-C5154A546B7A.jpeg)
https://www.fda.gov/drugs/news-events-human-drugs/50-years-progress-treating-patients-cancer
The P3 study of the DCVax-L cell-based platform technology is a landmark trial.
The P3 data were peer reviewed by independent physicians and qualified statisticians—please refer to JAMA Oncology. You might consider researching credible full-context sources to gather reliable information.
The DCVax-L cell-based technology has been under clinical investigation for a significant period of time, and the overall clinical data in total include three trials spanning many years. Safety and efficacy data have been gathered from trials with external controls and trials with placebo controls. The data include DCVax-L as a monotherapy and in combination with other agents.
The interim PD1 combo data are brilliant, and the trial is significant for a number of reasons relating to FDA guidelines and NIH peer-reviewed grant funding.
![](http://investorshub.advfn.com/uimage/uploads/2023/6/15/zrowdIMG_5729.jpeg)
https://clinicaltrials.gov/ct2/show/NCT04201873
https://www.fda.gov/media/120721/download
In the combo trial, patients who receive DCVax-L + placebo are being compared to patients who receive DCVax-L + pembrolizumab.
The control arm is receiving DCVax-L. While DCVax-L is not the current SOC, it is highly significant and notable that DCVax-L is being permitted to fill the role of SOC as the best available therapy within this combo study for rGBM. The combo trial also follows the P3 in sequence which in itself validates the findings of the P3 study—the placebo group in the PD1 study would not be receiving DCVax-L today if the preceding P3 trial had not proven its efficacy.
![](http://investorshub.advfn.com/uimage/uploads/2023/6/15/filslIMG_5730.jpeg)
The NIH is the most significant player in this game—If they had any doubt about the P3, the NIH would not continue their support and the FDA would not have permitted the combo trial to commence or continue.
https://clinicaltrials.gov/ct2/show/NCT04201873
The U.S. NIH has supported the DCVax-L platform for years, and the NIH renewed its support in 2022 to continue to fund the development of this technology and to fund research into combination therapies.
NIH-funded DCVax-L research is ongoing at UCLA today.
NIH grants are peer-reviewed and the research that NIH funds is highly scrutinized in advance of the award and also intermittently for the term of the various research projects.
![](http://investorshub.advfn.com/uimage/uploads/2023/2/4/bblriD9D7FB8C-F9D6-4CEC-879C-432859DD95D1.jpeg)
Mr. Newirth is another DCVax-L survivor well surpassing 10 years following a 2012 diagnosis! Congratulations!
https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/
June 13, 2023 Interview:
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
![](http://investorshub.advfn.com/uimage/uploads/2023/2/24/mcrygF9FFEBC7-09B0-45E7-B551-03E6603AC0BD.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/14/twavvIMG_5717.jpeg)
Explore Professor Keyoumars Ashkan's passion for neurosurgery and his love for @KingsCollegeNHS below as part of their #BrilliantPeople series🧠👇@KingsNeuro @KingsIoPPN https://t.co/yGKt2681Ie
— King's College London (@KingsCollegeLon) May 25, 2022
![](http://investorshub.advfn.com/uimage/uploads/2023/2/23/tfohwE018C05F-08DB-4AED-A8DB-098FF7D392BE.jpeg)
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
![](http://investorshub.advfn.com/uimage/uploads/2022/12/5/usbqx1B186F25-CAD8-40F5-8217-7AB247BDD9D6.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2022/11/17/bqbpv7C32BB8F-8F48-40E1-859C-A9265C9B08E2.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/2/23/qufjlE4F38319-DDD3-4B16-B383-29AB46BFC95D.jpeg)
https://www.theguardian.com/science/2022/nov/17/im-just-carrying-on-vaccine-gives-brain-cancer-patient-years-of-extra-life
https://www.braintumourresearch.org/stories/in-hope/in-hope-stories/kat-charles
![](http://investorshub.advfn.com/uimage/uploads/2023/2/4/rsmqxE5B4C9B5-9FC6-4E7D-883F-7433959BF74A.jpeg)
https://www.uclahealth.org/news/brain-cancer-discovery-clinical-trials
https://www.uclahealth.org/news/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020
![](http://investorshub.advfn.com/uimage/uploads/2023/6/14/gpuvfIMG_5718.jpeg)
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
![](http://investorshub.advfn.com/uimage/uploads/2022/12/5/tmdikA185EEB1-35A5-4A8C-8BCE-743F8B3C4EEF.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2022/12/1/uvyioE70AE832-1F13-4DB2-8CD3-F20008D28469.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2022/12/1/rhken0B334E26-EA09-40A7-94C5-51EA02B330DA.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2022/12/6/oogwl177AF295-D7AA-4488-8827-BE709EB1E861.jpeg)
September 2023
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/aqqlbIMG_5747.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/uznpdIMG_5753.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/wpvlcIMG_5749.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/[qklnIMG_5746.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/mjmdxIMG_5742.jpeg)
![](http://investorshub.advfn.com/uimage/uploads/2023/6/18/npzngIMG_5743.jpeg)
https://www.cns.org/annualmeeting
![Bullish](/static/images/ih2-bull.png)
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM